Higher ocrelizumab doses improve the benefit-risk profile among patients with relapsing multiple sclerosis treated with it for up to 10 years.

Efficacy of treatment is maintained during the switch from IV anti-CD20 therapies to ofatumumab in relapsing MS regardless of race/ethnicity.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis – Vidofludimus Calcium’s Activation of Nurr1 Reduces ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase II results of orelabrutinib ...

By Mongabay.com The Madras hedgehog, found only in southern India, is considered a species of least concern on the IUCN Red ...

The homes can open beds at the two state mental health hospitals and provide a place for patients to go when discharged.

A person’s precious organ donation came with an unexpected visitor. In a new paper out this month, scientists have documented ...

Since 2013, diagnoses of multiple sclerosis (MS) in Finland take less time after symptom onset and treatments follow the ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

Losing weight isn’t just about cutting calories—it’s a comprehensive health journey. Dr. Bharti Shetye, also known as Dr.